Intracellular hypoxia measured by (18)F-fluoromisonidazole positron emission tomography has prognostic impact in patients with estrogen receptor-positive breast cancer

BACKGROUND: Hypoxia is a key driver of cancer progression. We evaluated the prognostic impact of (18)F-fluoromisonidazole (FMISO) prior to treatment in patients with breast cancer. METHODS: Forty-four patients with stage II/III primary breast cancer underwent positron emission tomography/computed wi...

Descripción completa

Detalles Bibliográficos
Autores principales: Asano, Aya, Ueda, Shigeto, Kuji, Ichiei, Yamane, Tomohiko, Takeuchi, Hideki, Hirokawa, Eiko, Sugitani, Ikuko, Shimada, Hiroko, Hasebe, Takahiro, Osaki, Akihiko, Saeki, Toshiaki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6063018/
https://www.ncbi.nlm.nih.gov/pubmed/30053906
http://dx.doi.org/10.1186/s13058-018-0970-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6063018/
https://www.ncbi.nlm.nih.gov/pubmed/30053906
http://dx.doi.org/10.1186/s13058-018-0970-6

Ejemplares similares